Gunnar Gottschalk Ph.D., CEO and Section Chief, Translational Science

Dr. Gottschalk has been with Simmaron Research since its formation. Prior to attending graduate school, Dr. Gottschalk was the lead research coordinator for Sierra Internal Medicine and was responsible for the execution of several large multi-centered investigations in ME/CFS funded by NIH, The Chronic Fatigue Initiative, The Open Medicine Institute, and the Centers for Disease Control. In 2020, he was named the Foundation’s Executive Director. Since then, Dr. Gottschalk has served a dual role in the organization as the Executive Director and Principal Investigator. Throughout the COVID-19 pandemic, Dr. Gottschalk led Simmaron’s Local Response to COVID-19 Program in collaboration with Konstance Knox, PhD member of the Simmaron Scientific Advisory Board and CEO of Coppe Laboratories. This program provided free critical early access to COVID testing for residents of North Lake Tahoe, supported the development of the Simmaron COVID-19 Biobank and initiated a number of related research projects. In 2021, Dr. Gottschalk recruited Avik Roy, PhD, to be Simmaron’s Chief Scientific Officer. Since that time, the two have received multiple competitive grants including a Ramsay Award from SolveME and an NIH R21. At present, Dr. Gottschalk is the PI for Simmaron’s multi-centered clinical trial of Rapamycin in ME/CFS. His laboratory is located at the Indiana Center for Biomedical Innovation (ICBI) on the campus of the Indiana University Methodist Hospital in Indianapolis, IN.

https://www.ncbi.nlm.nih.gov/myncbi/1HMrmLhAo2aAln/bibliography/public/